p53 (7F5) Rabbi	t mAb				ell Signaling
Stor				Orders:	877-616-CELL (2355) orders@cellsignal.com
527				Support:	877-678-TECH (8324)
[‡] 252				Web:	info@cellsignal.com cellsignal.com
			3 Trask La	ne Danvers M	assachusetts 01923 USA
For Research Use Only. Not for U	-		0		Entern Oran Id
Applications: Reactiv WB, W-S, IHC-P, IF-IC, H Mk FC-FP, ChIP		MW (kDa): 53	Source/Isotype: Rabbit IgG	UniProt ID: #P04637	Entrez-Gene Id: 7157
Product Usage Information	For optimal ChIP results, us This antibody has been vali	se 2.5 µl of ar dated using \$	ntibody and 10 µg of chro SimpleChIP [®] Enzymatic (matin (approxima Chromatin IP Kits	ately 4 x 10 ⁶ cells) per IP.
	Application			D	ilution
	Western Blotting			1:	1000
	Simple Western™			1:	10 - 1:50
	Immunohistochemistry (Pa	raffin)		1:	80 - 1:320
	Immunofluorescence (Imm	unocytochen	nistry)	1:	800 - 1:1600
	Flow Cytometry (Fixed/Per	meabilized)			800 - 1:3200
	Chromatin IP			1:	200
Storage	Supplied in 10 mM sodium I 0.02% sodium azide. Store			ւg/ml BSA, 50% <u>g</u>	glycerol and less than
	For a carrier free (BSA and	azide free) v	ersion of this product see	product #74556	
Specificity / Sensitivity	p53 (7F5) Rabbit mAb detec mapped to the amino termir	-		tein. This antibod	ly binding has been
Source / Purification	Monoclonal antibody is proc	duced by imm	nunizing animals with a fu	Ill-length human p	53 fusion protein.
Background	The p53 tumor suppressor p genomic aberrations. Activa p53 is phosphorylated at mu damage induces phosphory p53 and its negative regulat for ubiquitination and protea PK at Ser15 and Ser37. Pho accumulation and activation p53 at Ser20, enhancing its vivo (10,11) and by CAK in and has been reported to in activation of p53 (10,13,14). <i>in vivo</i> (13,15). Phosphoryla Acetylation of p53 is mediat suppressing MDM2 from ree play a positive role in the ac human p53 becomes acetyl Deacetylation of p53 occurs in cellular aging and the DN	tion of p53 c ultiple sites <i>ir</i> dation of p53 tor, the oncop asomal degra osphorylation of p53 in res tetramerizati <i>vitro</i> (11). Ph fluence the g . p53 is phos ation of p53 a red by p300 <i>a</i> cruiting HDA cumulation of lated at Lys38 s through inte	an lead to either cell cycle or vivo and by several diffe- at Ser15 and Ser20 and protein MDM2 (4). MDM2 dation (5,6). p53 can be p in impairs the ability of MD sponse to DNA damage (ion, stability, and activity of posphorylation of p53 at S prowth suppressor function phorylated at Ser6 and S and CBP acetyltransferase C1 complex by p19 (ARF of p53 protein in stress res 82 (Lys379 in mouse) in w praction with the SIRT1 pr	e arrest and DNA erent protein kinas leads to a reduce inhibits p53 accu phosphorylated b M2 to bind p53, p 4,7). Chk2 and Ci (8,9). p53 is phos er392 is increase n, DNA binding, a er9 by CK1δ and lity of p53 to induce s. Inhibition of de) stabilizes p53. A sponse (17). Follo vivo to enhance p	repair or apoptosis (1). ses <i>in vitro</i> (2,3). DNA ed interaction between imulation by targeting it y ATM, ATR, and DNA- promoting both the hk1 can phosphorylate phorylated at Ser392 <i>in</i> ed in human tumors (12) and transcriptional CK1ɛ both <i>in vitro</i> and ce apoptosis (16). eacetylation Acetylation appears to pwing DNA damage, 53-DNA binding (18).
Background References	1. Levine, A.J. (1997) <i>Cell</i> 8 2. Meek, D.W. (1994) <i>Semir</i> 3. Milczarek, G.J. et al. (199 4. Shieh, S.Y. et al. (1997) <i>C</i> 5. Chehab, N.H. et al. (1997) <i>Fl</i> 6. Honda, R. et al. (1997) <i>Fl</i> 7. Tibbetts, R.S. et al. (1999) 8. Shieh, S.Y. et al. (1999) <i>E</i> 9. Hirao, A. et al. (2000) <i>Sci</i>	n Cancer Bio 07) Life Sci 60 Cell 91, 325-3 0) Proc Natl A EBS Lett 420 0) Genes Dev EMBO J 18, 1	0, 1-11. 34. Acad Sci U S A 96, 13777 0, 25-7. / 13, 152-7. L815-23.	-82.	

/24, 2:11 PM	 p53 (7F5) Rabbit mAb (#2527) Datasheet Without Images Cell Signaling Technology 10. Hao, M. et al. (1996) <i>J Biol Chem</i> 271, 29380-5. 11. Lu, H. et al. (1997) <i>Mol Cell Biol</i> 17, 5923-34. 12. Ullrich, S.J. et al. (1993) <i>Proc Natl Acad Sci U S A</i> 90, 5954-8. 13. Kohn, K.W. (1999) <i>Mol Biol Cell</i> 10, 2703-34. 14. Lohrum, M. and Scheidtmann, K.H. (1996) <i>Oncogene</i> 13, 2527-39. 15. Knippschild, U. et al. (1997) <i>Oncogene</i> 15, 1727-36. 16. Oda, K. et al. (2001) <i>EMBO J</i> 20, 1331-40. 18. Sakaguchi, K. et al. (1998) <i>Genes Dev</i> 12, 2831-41. 19. Solomon, J.M. et al. (2006) <i>Mol Cell Biol</i> 26, 28-38. 				
Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).				
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key	WB: Western Blotting W-S: Simple Western™ IHC-P: Immunohistochemistry (Paraffin) IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized) ChIP: Chromatin IP				
Cross-Reactivity Key	 H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected 				
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.				
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.				